Literature DB >> 1975197

Comparative beta-adrenoceptor blocking effects of propranolol, bisoprolol, atenolol, acebutolol and diacetolol on the human isolated bronchus.

E Naline1, B Sarria, O Ertzbischoff, P Ozanne, C Advenier.   

Abstract

Five beta-adrenoceptor blockers, propranolol, acebutolol, diacebutolol, atenolol and bisoprolol, were tested for their antagonistic effect against isoprenaline on human isolated bronchi. The results showed (1) that only propranolol exerted a competitive antagonistic effect against isoprenaline (pA2 = 9.40 +/- 0.22, n = 7) whereas the other drugs did not, and (2) that, in the presence of beta-adrenoceptor blockers in the plasma concentrations reported after a single usual therapeutic dose, the doses of isoprenaline giving the same bronchodilator effect must be multiplied by 32.6, 5.51, 4.63, 2.82 and 1.95 respectively with propranolol, diacetolol, acebutolol, atenolol, and bisoprolol. It was concluded that (1) atenolol and bisoprolol were the least potent drugs at bronchial level in therapeutic plasma concentrations and (2) that tests performed on the human isolated bronchus might be a useful screening procedure for new drugs with potential activity on the airways.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975197      PMCID: PMC1368285          DOI: 10.1111/j.1365-2125.1990.tb03753.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.

Authors:  R E Ruffin; P A Frith; R C Anderton; C R Kumana; M T Newhouse; F E Hargreave
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

2.  Comparison of the beta 1 and beta 2 adrenoceptor blocking properties of acebutolol and propranolol.

Authors:  T L Whitsett; D C Levin; C V Manion
Journal:  Chest       Date:  1982-12       Impact factor: 9.410

3.  Assessment of bronchial beta blockade after oral bevantolol.

Authors:  A D Mackay; H R Gribbin; C J Baldwin; A E Tattersfield
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

4.  Systemic bioavailability of acebutolol in man.

Authors:  A Roux; B Flouvat; Y Fouache; J P Bourdarias
Journal:  Biopharm Drug Dispos       Date:  1983 Jul-Sep       Impact factor: 1.627

5.  Antihypertensive effect of diacetolol in essential hypertension.

Authors:  M Thibonnier; C Flabeau; M Thouvenin; A Roux; B Flouvat; P Pasquier; J Menard
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

6.  Asthma and beta-blockers.

Authors:  D S Lawrence; J N Sahay; S S Chatterjee; J M Cruickshank
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Atenolol interaction with aspirin, allopurinol, and ampicillin.

Authors:  M Schäfer-Korting; W Kirch; T Axthelm; H Köhler; E Mutschler
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

8.  Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction.

Authors:  W H Perks; S S Chatterjee; R S Croxson; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

9.  Ventilatory and haemodynamic effects of terbutaline infusion during beta 1-selective blockade with metoprolol and acebutolol in asthmatic patients.

Authors:  A P Greefhorst; C L van Herwaarden
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Bronchial and cardiac beta-adrenoceptor blockade--a comparison of atenolol, acebutolol and labetalol.

Authors:  H R Gribbin; A D Mackay; C J Baldwin; A E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

View more
  1 in total

1.  Use of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials.

Authors:  Virginia Norris; Claire Ambery
Journal:  Drugs R D       Date:  2014-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.